• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Preemptive Dose Optimization Using Therapeutic Drug Monitoring for Biologic Therapy of Crohn's Disease: Avoiding Failure While Lowering Costs?

作者信息

Vande Casteele Niels, Gils Ann

机构信息

Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven - University of Leuven, Herestraat 49, PO 820, 3000, Leuven, Belgium,

出版信息

Dig Dis Sci. 2015 Sep;60(9):2571-3. doi: 10.1007/s10620-015-3673-1. Epub 2015 Apr 28.

DOI:10.1007/s10620-015-3673-1
PMID:25917050
Abstract
摘要

相似文献

1
Preemptive Dose Optimization Using Therapeutic Drug Monitoring for Biologic Therapy of Crohn's Disease: Avoiding Failure While Lowering Costs?利用治疗药物监测对克罗恩病生物治疗进行预先剂量优化：在降低成本的同时避免治疗失败？
Dig Dis Sci. 2015 Sep;60(9):2571-3. doi: 10.1007/s10620-015-3673-1. Epub 2015 Apr 28.
2
Importance of defining loss of response before therapeutic drug monitoring.在治疗药物监测前定义反应丧失的重要性。
Gut. 2015 Mar;64(3):516-7. doi: 10.1136/gutjnl-2014-307877. Epub 2014 Jul 16.
3
A measured approach to Crohn's therapy: check levels and save.克罗恩病治疗的精准方法：检测水平并节约成本。
Gastroenterology. 2014 Nov;147(5):1174-5. doi: 10.1053/j.gastro.2014.09.006. Epub 2014 Sep 18.
4
Authors' response: Importance of defining loss of response before therapeutic drug monitoring.作者回应：在治疗药物监测之前定义反应丧失的重要性。
Gut. 2015 Aug;64(8):1340-1. doi: 10.1136/gutjnl-2014-309044. Epub 2015 Jan 14.
5
Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab.与英夫利昔单抗治疗失败的克罗恩病患者强化剂量治疗相比，个体化治疗是一种长期具有成本效益的方法。
Dig Dis Sci. 2015 Sep;60(9):2762-70. doi: 10.1007/s10620-015-3581-4. Epub 2015 Feb 12.
6
Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.在对 TNF 治疗应答丧失的克罗恩病患者中，个体化治疗比剂量强化更具成本效益：一项随机对照试验。
Gut. 2014 Jun;63(6):919-27. doi: 10.1136/gutjnl-2013-305279. Epub 2013 Jul 22.
7
Earlier need of infliximab intensification in ulcerative colitis than in Crohn's disease.溃疡性结肠炎比克罗恩病更早需要强化英夫利昔单抗治疗。
J Crohns Colitis. 2014 Oct;8(10):1331-2. doi: 10.1016/j.crohns.2014.03.007. Epub 2014 Mar 29.
8
Case report: combination therapy with granulocyte apheresis and infliximab for refractory Crohn's disease.病例报告：粒细胞单采术与英夫利昔单抗联合治疗难治性克罗恩病
J Clin Apher. 2006 Dec;21(4):249-51. doi: 10.1002/jca.20093.
9
Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.根据英夫利昔单抗的血药浓度指导炎症性肠病患者的给药剂量。
Gastroenterology. 2015 Jun;148(7):1320-9.e3. doi: 10.1053/j.gastro.2015.02.031. Epub 2015 Feb 24.
10
Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.与英夫利昔单抗相比，接受阿达木单抗治疗的克罗恩病门诊患者出现继发性反应丧失和需要增加剂量的时间更早：一项真实队列研究。
J Crohns Colitis. 2014 Nov;8(11):1454-63. doi: 10.1016/j.crohns.2014.05.007. Epub 2014 Jun 16.

引用本文的文献

1
Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer.基于帕博利珠单抗的治疗方案中延长给药间隔或延迟给药与晚期非小细胞肺癌生存结局的关系。
Clin Lung Cancer. 2021 May;22(3):e379-e389. doi: 10.1016/j.cllc.2020.05.028. Epub 2020 Jun 5.
2
Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors.基于计算机模拟的单克隆抗体免疫检查点抑制剂延长给药方案的应用机会。
Br J Clin Pharmacol. 2020 Sep;86(9):1769-1777. doi: 10.1111/bcp.14369. Epub 2020 Jun 11.
3
Recent advances in understanding and managing pediatric inflammatory bowel disease.

本文引用的文献

1
Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.根据英夫利昔单抗的血药浓度指导炎症性肠病患者的给药剂量。
Gastroenterology. 2015 Jun;148(7):1320-9.e3. doi: 10.1053/j.gastro.2015.02.031. Epub 2015 Feb 24.
2
Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice.抗TNF单克隆抗体在炎症性肠病中的药代动力学：为当前治疗增添价值。
J Clin Pharmacol. 2015 Mar;55 Suppl 3:S39-50. doi: 10.1002/jcph.374.
3
Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab.
小儿炎症性肠病的认识与管理的最新进展
F1000Res. 2019 Dec 13;8. doi: 10.12688/f1000research.19609.1. eCollection 2019.
4
Individualized Dosing of Therapeutic Monoclonal Antibodies-a Changing Treatment Paradigm?治疗性单克隆抗体的个体化剂量——治疗范式的改变？
AAPS J. 2018 Sep 5;20(6):99. doi: 10.1208/s12248-018-0257-y.
5
Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease.主动监测英夫利昔单抗在反应性检测后优于单独反应性检测在炎症性肠病患者中的临床结局。
J Crohns Colitis. 2018 Jun 28;12(7):804-810. doi: 10.1093/ecco-jcc/jjy039.
6
Infliximab Dosing Strategies and Predicted Trough Exposure in Children With Crohn Disease.英夫利昔单抗给药策略及克罗恩病患儿预测谷浓度暴露情况
J Pediatr Gastroenterol Nutr. 2016 May;62(5):723-7. doi: 10.1097/MPG.0000000000001123.
7
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management.对抗肿瘤坏死因子治疗反应丧失：定义、流行病学及管理
Clin Transl Gastroenterol. 2016 Jan 7;7(1):e135. doi: 10.1038/ctg.2015.63.
与英夫利昔单抗治疗失败的克罗恩病患者强化剂量治疗相比，个体化治疗是一种长期具有成本效益的方法。
Dig Dis Sci. 2015 Sep;60(9):2762-70. doi: 10.1007/s10620-015-3581-4. Epub 2015 Feb 12.
4
A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity.一项回顾性分析：用于评估克罗恩病活动度的患者报告结局指标的发展
Aliment Pharmacol Ther. 2015 Jan;41(1):77-86. doi: 10.1111/apt.13001. Epub 2014 Oct 27.
5
A review of CT-P13: an infliximab biosimilar.CT-P13综述：英夫利昔单抗生物类似药
BioDrugs. 2014 Jun;28(3):313-21. doi: 10.1007/s40259-014-0094-1.
6
Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.在对 TNF 治疗应答丧失的克罗恩病患者中，个体化治疗比剂量强化更具成本效益：一项随机对照试验。
Gut. 2014 Jun;63(6):919-27. doi: 10.1136/gutjnl-2013-305279. Epub 2013 Jul 22.
7
ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).ECCO 立场声明：生物类似药在炎症性肠病（IBD）治疗中的应用。
J Crohns Colitis. 2013 Aug;7(7):586-9. doi: 10.1016/j.crohns.2013.03.011. Epub 2013 Apr 25.
8
Antibody response to infliximab and its impact on pharmacokinetics can be transient.英夫利昔单抗的抗体应答及其对药代动力学的影响可能是短暂的。
Am J Gastroenterol. 2013 Jun;108(6):962-71. doi: 10.1038/ajg.2013.12. Epub 2013 Feb 19.
9
Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.炎症性肠病的医疗费用已经从住院和手术转向抗 TNFα 治疗：来自 COIN 研究的结果。
Gut. 2014 Jan;63(1):72-9. doi: 10.1136/gutjnl-2012-303376. Epub 2012 Nov 7.
10
Hospitalisations and surgery in Crohn's disease.克罗恩病的住院治疗和手术。
Gut. 2012 Apr;61(4):622-9. doi: 10.1136/gutjnl-2011-301397. Epub 2012 Jan 20.